Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy

Conditions

• Psoriasis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Deucravacitinib — DRUG
  According to the product label

Study Details

The purpose of this study is to characterize the real-life experience of patients with moderate/severe psoriasis receiving deucravacitinib treatment, in terms of efficacy, safety, and health-related quality of life (HRQoL) in Italy

Key Dates

Start date

Aug 5, 2025

Status verified

Nov 2025

Primary completion

Jul 5, 2027

Completion

Aug 5, 2027

Study Design

Enrollment

200 participants (estimated)

Arms

• Arm: Cohort 1
  Participants with moderate/severe psoriasis receiving deucravacitinib

Primary Outcome Measure

The percentage of participants still receiving deucravacitinib treatment [ Time Frame: Week 24 and 52 ]

Central Contacts

• BMS Study Connect Contact Center www.BMSStudyConnect.com
  855-907-3286
  [email protected]
• First line of the email MUST contain NCT # and Site #

Related Studies

• Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
  Recruiting · University of California, San Diego · La Jolla, California
• Regulation of Inflammatory Genes in Psoriasis
  Recruiting · University of Alabama at Birmingham · Birmingham, Alabama
• LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis
  Enrolling By Invitation · Bausch Health Americas, Inc. · Bridgewater, New Jersey
• An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients
  Recruiting · Psoriasis Treatment Center of Central New Jersey · East Windsor, New Jersey